Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection
- PMID: 28540757
- PMCID: PMC5665362
- DOI: 10.1089/AID.2015.0340
Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection
Abstract
The human T cell lymphotropic virus type 1 (HTLV-1) is the etiologic agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 infected individuals have increased susceptibility to Mycobacterium tuberculosis infection but the influence of tuberculosis (TB) on the course of HTLV-1 infection is unknown. The aim of this study was to evaluate the influence of TB on immunological, virologic, and neurologic features of HTLV-1 infection. This is a retrospective analysis of individuals enrolled in a cohort study from an HTLV-1 clinic who were evaluated for past or latent tuberculosis (LTB) and classified clinically as HTLV-1 carriers, probable HAM/TSP and definite HAM/TSP. Spontaneous cytokine production (interferon-gamma [IFN-γ], tumor necrosis factor [TNF], and interleukin[IL]-10), serum chemokines (CXCL9 and CXCL10) and HTLV-1 proviral load were evaluated. Of 172 participants, 64 did not have histories of TB (TB- group), 81 had LTB and 27 had TB in the past (TB+ group). In the TB+ group, there was a higher frequency of HAM/TSP patients (35%) than in HTLV-1 carriers (10%) (OR = 3.8, p = .0001). HAM/TSP patients with histories of TB had higher IFN-γ/IL-10 and TNF/IL-10 ratios when compared with HAM/TSP patients without histories of TB. There were no differences in serum chemokine production and proviral load across TB groups stratified on HTLV-1 clinical status. In conclusion, TB may influence the development of HAM/TSP, and patients with these two diseases have an impairment in the modulation of immune response.
Keywords: HTLV-1; immune response; tuberculosis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).Acta Trop. 2013 Jan;125(1):75-81. doi: 10.1016/j.actatropica.2012.09.012. Epub 2012 Sep 27. Acta Trop. 2013. PMID: 23022356
-
Mediators Go Together: High Production of CXCL9, CXCL10, IFN-γ, and TNF-α in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.AIDS Res Hum Retroviruses. 2017 Nov;33(11):1134-1139. doi: 10.1089/AID.2016.0296. Epub 2017 Jul 25. AIDS Res Hum Retroviruses. 2017. PMID: 28648091
-
Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP.J Med Virol. 2011 Jul;83(7):1269-74. doi: 10.1002/jmv.22087. J Med Virol. 2011. PMID: 21567429
-
[Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].Rev Neurol. 2009 Feb 1-15;48(3):147-55. Rev Neurol. 2009. PMID: 19206063 Review. Spanish.
-
Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.Rev Neurol (Paris). 2012 Mar;168(3):257-69. doi: 10.1016/j.neurol.2011.12.006. Epub 2012 Mar 7. Rev Neurol (Paris). 2012. PMID: 22405461 Review.
Cited by
-
Factors Influencing the Indeterminate Results in a T-SPOT.TB test: A Matched Case-control Study.Intern Med. 2023 Nov 15;62(22):3321-3326. doi: 10.2169/internalmedicine.1006-22. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005270 Free PMC article.
-
HTLV-1 and Co-infections.Front Med (Lausanne). 2022 Feb 3;9:812016. doi: 10.3389/fmed.2022.812016. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35187000 Free PMC article. Review.
-
Overview on coinfection of HTLV-1 and tuberculosis: Mini-review.J Clin Tuberc Other Mycobact Dis. 2021 Feb 19;23:100224. doi: 10.1016/j.jctube.2021.100224. eCollection 2021 May. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 33681477 Free PMC article. Review.
-
Making Visible HTLV Infection in a Non-endemic Area of Argentina.Front Med (Lausanne). 2022 Jul 8;9:892159. doi: 10.3389/fmed.2022.892159. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35879924 Free PMC article.
-
Evaluation of QuantiFERON-TB Gold for the Diagnosis of Mycobacterium tuberculosis Infection in HTLV-1-Infected Patients.Viruses. 2024 Nov 30;16(12):1873. doi: 10.3390/v16121873. Viruses. 2024. PMID: 39772183 Free PMC article.
References
-
- Gessain A, Barin F, Vernant JC, et al. : Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407–410 - PubMed
-
- Osame M, Usuku K, Izumo S, et al. : HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031–1032 - PubMed
-
- Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B: HTLV-I in the general population of Salvador, Brazil: A city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr 2003;34:527–531 - PubMed
-
- Catalan-Soares B, Carneiro-Proietti AB, Proietti FA: Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): Serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica 2005;21:926–931 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous